Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MannKind Corporation (MNKD), Sarepta Therapeutics Inc (SRPT): Why You Shouldn’t Buy Stocks in Biotech

Page 1 of 2

How can you double your investment literally overnight? Buy stocks of the right biotech companies. However, you can also cut your investment by half overnight by buying the wrong biotech stocks. The reality is that not everyone is cut out for the sometimes crazy world of biotech investing. If any of the following criteria apply to you, you probably shouldn’t buy stocks in biotech.

MannKind Corporation (NASDAQ:MNKD)

1. You don’t know what you don’t know.
You don’t have to know everything to be a successful biotech investor. However, you do have to realize that you don’t know everything — and make decisions accordingly.

Let’s look at an example of a hypothetical investor we’ll call Joe. In April 2010, Joe saw that the Food and Drug Administration approved a new prostate cancer vaccine, Provenge, which was developed by Dendreon Corporation (NASDAQ:DNDN). Provenge looked very promising, with one prominent analyst forecasting peak annual sales as high as $4 billion.

Joe noted that Dendreon’s stock was up more than 30% for the year and had more than quintupled in the last 12 months. He thought to himself, “Great stock! Great potential! This is a sure thing!” So, Joe loaded up on shares of Dendreon. Unfortunately, Joe didn’t know what he didn’t know.

He had no idea that doctors would be hesitant to prescribe Provenge due to concerns about reimbursement. Joe didn’t realize that analysts are frequently overly optimistic when making sales projections for new treatments. It was an expensive lesson for him. Dendreon Corporation (NASDAQ:DNDN)’s stock sold for more than $40 per share in early April 2010. The stock’s current price is around $4 per share.

2. You can’t afford to lose.
Too many people invest money that they can’t afford to lose — and then proceed to lose. As with any other sector in the market, you’re going to have some biotech stocks that perform well and others that perform horribly. The key is to not risk more than you’re prepared to lose.

Biotech stocks are highly volatile. A good example of this is Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Spectrum rode a wave of generic leucovorin shortages in late 2010 and early 2011 to stock gains of more than 170%. Shares then plunged more than 30% from July through September 2011. But the ride wasn’t over yet.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s stock price nearly doubled over the next three months. And then it fell 37% before climbing back to hit new all-time highs. However, shares now stand at nearly half of where the stock traded in July 2012.

At several points along the way, you could have been a big winner if you held Spectrum shares. Unfortunately, you could also have been a big loser depending on when you bought the stock. If you’re not prepared to lose money with the volatile nature of biotech stocks, it’s probably best to stay away.

3. You aren’t willing to wait.
This crazy volatility can shake out many investors. However, some biotechs take years to achieve their potential. If you aren’t willing to wait for success, biotech investing probably isn’t for you.

MannKind Corporation (NASDAQ:MNKD) presents a textbook case for the importance of waiting. The company first attempted to gain regulatory approval for its inhalable insulin product, Afrezza, back in 2010.
Then in 2011, MannKind Corporation (NASDAQ:MNKD) received another thumbs down from the FDA. Shares have risen and fallen more than 40% multiple times in the meantime.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!